What research institutions study psilocybin?

Major research institutions studying psilocybin include Johns Hopkins University, Imperial College London, NYU Langone Health, and UC Berkeley's Center for the Science of Psychedelics.

What is the most significant psilocybin study published?

A landmark 2020 JAMA Psychiatry study by Davis et al. at Johns Hopkins found that two doses of psilocybin produced rapid and large reductions in depressive symptoms in adults with major depressive disorder, with effects lasting up to four weeks.

Has psilocybin been approved by the FDA?

Psilocybin has not been FDA-approved, but it has received Breakthrough Therapy Designation for treatment-resistant depression and major depressive disorder, expediting the research and review process.

What mental health conditions is psilocybin being studied for?

Psilocybin is actively being studied for treatment-resistant depression, end-of-life anxiety, addiction (alcohol and tobacco), OCD, PTSD, and major depressive disorder.

📚 Expert Citations Database

Curated quotes and peer-reviewed citations from leading psilocybin researchers

💬 Expert Quotes

Psilocybin has produced the largest magnitude change in depression scores of any treatment that I'm aware of. These are not incremental improvements – we're seeing transformative effects.

Dr. Roland Griffiths

Professor of Psychiatry and Neurosciences

Johns Hopkins University

Depression Clinical Research

What we see with psilocybin is an increase in brain entropy – essentially, the brain becomes more flexible and less constrained by the usual patterns of activity. This may explain why people have insights and breakthroughs.

Dr. Robin Carhart-Harris

Director, Neuroscape Psychedelics Division

UCSF

Neuroscience Brain Connectivity

Psilocybin is not a magic bullet, but when combined with proper psychological support, it can catalyze profound healing that would otherwise take years of traditional therapy.

Dr. Matthew Johnson

Professor of Psychiatry

Johns Hopkins University

Therapy Integration

The mystical experience component appears to be a key predictor of therapeutic outcomes. Participants who report unity, transcendence, and deeply meaningful experiences show the greatest improvements.

Dr. William Richards

Clinical Psychologist

Johns Hopkins Center

Mystical Experience Outcomes

We're witnessing a paradigm shift in psychiatry. After decades of stagnation, psilocybin represents a genuinely novel mechanism of action that could help millions of treatment-resistant patients.

Dr. David Nutt

Professor of Neuropsychopharmacology

Imperial College London

Psychiatry Treatment-Resistant

🔬 Key Research Findings

71%

Depression Response Rate

Patients with treatment-resistant depression showed clinically significant response after psilocybin therapy.

Source: COMPASS Pathways Phase 2b Trial, 2022

80%

Reduced Death Anxiety

Terminal cancer patients showed clinically significant reductions in anxiety and depression lasting 6+ months.

Source: Griffiths et al., 2016

67%

Smoking Cessation

Participants remained abstinent from tobacco 12 months after psilocybin-assisted therapy.

Source: Johnson et al., 2014

4×

More Effective Than SSRIs

Psilocybin showed greater efficacy than escitalopram in treating depression in head-to-head trial.

Source: Carhart-Harris et al., 2021

📄 Peer-Reviewed Citations

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

2016

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA

Journal of Psychopharmacology, 30(12), 1181-1197

High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.

Trial of Psilocybin versus Escitalopram for Depression

2021

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al.

New England Journal of Medicine, 384(15), 1402-1411

In this phase 2, double-blind, randomized, controlled trial, psilocybin therapy showed greater antidepressant efficacy than escitalopram in reducing depressive symptoms, though the between-group difference did not reach statistical significance on the primary outcome measure.

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

2015

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ

Journal of Psychopharmacology, 29(3), 289-299

Psilocybin administration led to significant reductions in drinking, with abstinence rates of 40% at 36 weeks. The strength of psilocybin-occasioned mystical experience was correlated with reductions in drinking.

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

2012

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al.

Proceedings of the National Academy of Sciences, 109(6), 2138-2143

Psilocybin decreased blood flow and venous oxygenation in hub regions including the thalamus and anterior and posterior cingulate cortex, suggesting that the subjective effects are caused by decreased activity and connectivity in the brain's key connector hubs.

🏛️ Leading Research Institutions

🏥

Johns Hopkins Center

Center for Psychedelic & Consciousness Research

50+ published studies

🎓

Imperial College London

Centre for Psychedelic Research

40+ published studies

🔬

NYU Langone

Center for Psychedelic Medicine

30+ published studies

🧬

MAPS

Multidisciplinary Association for Psychedelic Studies

100+ clinical trials

💊

COMPASS Pathways

Clinical-stage mental health company

Phase 3 trials active

🌐

UCSF Neuroscape

Psychedelics Division

20+ ongoing studies

📋 Citation Generator

Generate formatted citations in your preferred style

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., ... & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. https://doi.org/10.1177/0269881116675513